246
Participants
Start Date
April 30, 2014
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Placebo
Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
RSV sF 20 mcg
Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
MEDI7510 (20 mcg RSV sF)
Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
RSV sF 50 mcg
Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
MEDI7510 (50 mcg RSV sF)
Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
RSV sF 80 mcg
Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
MEDI7510 (80 mcg RSV sF)
Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
Accelovance, Inc, Rockville
Compass Research, Orlando
Miami Research Associates, Miami
Lead Sponsor
MedImmune LLC
INDUSTRY